Search Results - David Bickel

  • Showing 1 - 3 results of 3
Refine Results
  1. 1

    Identification of non-charged 7.44 analogs interacting with the NHR2 domain of RUNX1-ETO with improved antiproliferative effect in RUNX-ETO positive cells by Mohanraj Gopalswamy, David Bickel, Niklas Dienstbier, Jia-Wey Tu, Melina Vogt, Stephan Schott-Verdugo, Sanil Bhatia, Manuel Etzkorn, Holger Gohlke

    Published in Scientific Reports (2025-05-01)
    Get full text
    Article


  2. 2

    Biophysical and pharmacokinetic characterization of a small-molecule inhibitor of RUNX1/ETO tetramerization with anti-leukemic effects by Mohanraj Gopalswamy, Tobias Kroeger, David Bickel, Benedikt Frieg, Shahina Akter, Stephan Schott-Verdugo, Aldino Viegas, Thomas Pauly, Manuela Mayer, Julia Przibilla, Jens Reiners, Luitgard Nagel-Steger, Sander H. J. Smits, Georg Groth, Manuel Etzkorn, Holger Gohlke

    Published in Scientific Reports (2022-08-01)
    Get full text
    Article


  3. 3

    Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells by Melina Vogt, Niklas Dienstbier, Julian Schliehe-Diecks, Katerina Scharov, Jia-Wey Tu, Philip Gebing, Julian Hogenkamp, Berna-Selin Bilen, Silke Furlan, Daniel Picard, Marc Remke, Layal Yasin, David Bickel, Munishikha Kalia, Alfredo Iacoangeli, Thomas Lenz, Kai Stühler, Aleksandra A. Pandyra, Julia Hauer, Ute Fischer, Rabea Wagener, Arndt Borkhardt, Sanil Bhatia

    Published in Cell Death and Disease (2023-12-01)
    Get full text
    Article


Search Tools: